Special Report: The Lab Kickback Risks of “Freebies”
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
Author Information
By Glenn S. Demby | May 9, 2024
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
By Glenn S. Demby | Feb 27, 2024
Strategies to avoid compliance issues related to registries, space rentals, and other common incentives.
By Glenn S. Demby | Feb 23, 2024
Recent cases involve another fraud related to finger prick blood testing, as well as alleged malpractice and discrimination.
By Glenn S. Demby | Jan 26, 2024
When structuring business arrangements, addressing six key risk areas can help laboratories avoid major compliance issues.
By Glenn S. Demby | Jan 9, 2024
Though things appeared status quo in 2023, last year may prove to be a turning point for the laboratory industry.
By Glenn S. Demby | Jan 9, 2024
An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.
By Glenn S. Demby | Jan 9, 2024
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
By Glenn S. Demby | Jan 4, 2024
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
By Glenn S. Demby | Jan 2, 2024
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
By Glenn S. Demby | Jan 2, 2024
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.